| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| WAVE LIFE SCIENCES | 17 | 2 | 0,00 % | ||
| DYNE THERAPEUTICS | 16 | - | 0,00 % | ||
| STRUCTURE THERAPEUTICS | 14 | 1 | 0,00 % | ||
| KYMERA THERAPEUTICS | 13 | 6 | 0,00 % | ||
| BIONTECH | 12 | 13 | +0,42 % | ||
| MIRUM PHARMACEUTICALS | 11 | 1 | -0,85 % | ||
| PRAXIS PRECISION MEDICINES | 8 | - | 0,00 % | ||
| TERNS PHARMACEUTICALS | 7 | 2 | 0,00 % | ||
| INCYTE | 6 | 25 | +0,41 % | ||
| HUTCHMED | 6 | 7 | -0,87 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:31 | Why Structure Therapeutics Stock Doubled and Then Some on Monday | 1 | The Motley Fool | ||
| 01:01 | Why Wave Life Sciences Stock Vaulted 146% Higher on Monday | 2 | The Motley Fool | ||
| 00:36 | Biogen Inc.: "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List | 2 | GlobeNewswire (USA) | ||
| 00:31 | Why Recursion Pharamaceuticals Topped the Market Today | 3 | The Motley Fool | ||
| 00:26 | Wave Life Sciences Ltd. (WVE): A Bull Case Theory | 1 | Insider Monkey | ||
| 00:06 | Oppenheimer raises Terns Pharmaceuticals stock price target to $58 on CML drug data | 1 | Investing.com | ||
| Mo | Kymera Therapeutics stock price target raised to $138 from $75 at BTIG | 2 | Investing.com | ||
| Mo | Structure Therapeutics stock price target raised to $90 by Stifel | 3 | Investing.com | ||
| Mo | Pliant Therapeutics trennt sich von Medizinischem Vorstand Dr. Éric Lefebvre | - | Investing.com Deutsch | ||
| Mo | BTIG hebt Kursziel für Kymera Therapeutics auf 138 Dollar an | - | Investing.com Deutsch | ||
| Mo | Stifel hebt Kursziel für Structure Therapeutics auf 90 US-Dollar an | 2 | Investing.com Deutsch | ||
| Mo | Structure Therapeutics: Aktie fällt nach geplanter 500-Millionen-Dollar-Kapitalerhöhung | 1 | Investing.com Deutsch | ||
| Mo | Incyte's experimental drug shows strong response in blood disorder | 5 | Investing.com | ||
| Mo | Vera Therapeutics announces $200M public offering | 2 | Seeking Alpha | ||
| Mo | Genmab A/S: Genmab Announces New Data from Phase 1b/2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) | 184 | Business Wire | Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment... ► Artikel lesen | |
| Mo | Jim Lang elected to Halozyme's board of directors | 2 | Investing.com | ||
| Mo | Wave Life Sciences announces $250M public offering and pre-funded warrants | 2 | Seeking Alpha | ||
| Mo | Autolus reports positive early data from lupus treatment trial | 1 | Investing.com | ||
| Mo | Dyne Therapeutics launches $300 million common stock offering | 1 | Investing.com | ||
| Mo | Amit Munshi joins Arcutis board as founder Chaudhuri retires | 1 | Investing.com |